CBS News (Video) on MSN1d
What possible compounded semaglutide ban means for patientsThe FDA declared the shortage of Novo Nordisk's weight-loss drugs over, giving compounders until May to stop making alternatives. An industry group representing compounders is suing. Dr. Angela Fitch ...
After quite a crushing bull stampede in 2024, the stock price of weight loss drug star Novo Nordisk (NYSE: NVO) has come down ...
MOBILE, Ala. (WKRG) — Saad Healthcare — with locations in Mobile and Baldwin counties — has agreed to pay a $3 million ...
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
NEW YORK, NY / ACCESS Newswire / February 23, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Minnesota law enforcement agencies are getting high-tech help to crack down on distracted driving. Trump’s endorsement helped ...
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...
Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...
Local companies are developing technologies that they hope could replace a painful poke with something that feels more like ...
Hartenstein supplied 10 points (5-6 FG), 12 rebounds, one assist and two blocks in 27 minutes during Thursday's 116-101 loss to the Timberwolves. It was the 19th double-double of the season for ...
In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two companies have approved weight loss drugs that are generating billions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results